TRUST-III: what clinicians are saying
taletrectinib in TKI-naïve ROS1-positive locally advanced/metastatic non-small cell lung cancer · NCT06564324 ↗ · Phase 3 · Nuvation Bio Inc.
A medical oncologist discussing TRUST-III sees taletrectinib as a possible class leader based on earlier-study comparisons, not trial outcomes. A physician who described helping conduct a matching-adjusted indirect comparison interprets it as favoring taletrectinib over crizotinib, but reports comparable severe treatment-related adverse events. The medical oncologist’s praise for CNS activity and neurologic tolerability does not establish an overall safety advantage. The sources reviewed for this edition contain no results from the trial.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 12 verified statements
3 findings, and what sits behind each
01. Taletrectinib efficacy: what clinicians highlight in indirect TKI-naïve comparisons
2 of the report's 2 cited clinicians · 5 statements from 2 speakers in 2 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 3.
Draws on: The comparison, Secondary endpoints, Primary endpoint: PFS (Assessed by BIRC), Population and setting, Safety and tolerability, Design and conduct.
02. CNS: what most speakers highlight; a clinician sees similar MAIC grade ≥3 TRAE rates
2 of the report's 2 cited clinicians · 4 statements from 3 speakers in 3 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Safety and tolerability, The comparison, Primary endpoint: PFS (Assessed by BIRC), Population and setting, Design and conduct.
03. MAIC: a clinician values it pending phase 3 data, but favors direct trials
1 of the report's 2 cited clinicians · 4 statements from 1 speaker in 1 source, a podcast or video · 3 passages
Limitations recorded: 3.
Draws on: Design and conduct, Population and setting, Primary endpoint: PFS (Assessed by BIRC), Secondary endpoints, The comparison, Safety and tolerability.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 3
2 of the report's 2 cited clinicians
Taletrectinib efficacy: what clinicians highlight in indirect TKI-naïve comparisons
5 statements from 2 speakers in 2 sources, 1 of them a podcast or video
2 of the 2 named speakers in this finding hold this view, each a confirmed clinician
- 5
- statements
- 4
- passages
- 2
- sources
- 2
- speakers
What the statements areViews 2Questions and uncertainty 0Clinical experience 0Comparisons 2Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 5Giving context 2Recorded with the findingLimitations: 3
1 post or article · 1 podcast or video
Draws on: The comparison, Secondary endpoints, Primary endpoint: PFS (Assessed by BIRC), Population and setting, Safety and tolerability, Design and conduct.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (7)
CNS, central nervous system; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; NSCLC, non-small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
The full TRUST-III report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians still need to see from TRUST-III on progression-free and overall survival to guide taletrectinib versus crizotinib use in TKI-naïve, locally advanced or metastatic ROS1-positive NSCLC?
From findings F1 (5 statements from 2 speakers in 2 sources) and F3 (4 statements from 1 speaker in 1 source). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 10commentary sources screened
- 4sources cited by verified statements
- 3named in screened sources
- 3speakers cited in the report
- 3cited speakers with a verified identity
2 cited clinicians, speakers with a confirmed clinical role, of them 2 physicians. By role and specialty:
- 1 physician, specialty not confirmed
- 1 physician, Medical oncology
- 12verified statements, each linked to its source
- 9of them from speakers with a confirmed clinical role
- 3findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 4 sections | Paid |
| Verified statements with short source quotes and links | 12 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 2 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 3 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 7 | Free |
| Sources with links | 4 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
7 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: PFS (Assessed by BIRC) | 3 | 2 |
| Secondary endpoints | 6 | 3 |
| Population and setting | 3 | 2 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 6 | 3 |
| Safety and tolerability | 4 | 3 |
| Design and conduct | 3 | 1 |
| Role of MAIC and real-world analyses alongside direct comparisons | 4 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
12 verified statements from 4 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 7 statements · 58% | ||||
| YouTube | 7 | 1 | 1 | |
| Podcasts | 0 | 0 | 1 | |
| Posts · 3 statements · 25% | ||||
| X threads | 3 | 2 | 8 | |
| Primary sources · 2 statements · 17%cited for context, not screened | ||||
| Registry | 2 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 3 / quarter
- Screened window
- Oct 15, 2024 → Oct 29, 2026
- Cited window
- Apr 7, 2025 → Aug 27, 2025
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- Registry
- NCT06564324
- Study IDs
- AB-106-G318
- Sponsor
- Nuvation Bio Inc.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 194 estimated
- Registered
- 2024-08-21
- Start
- 2024-11-27 actual
- Primary completion
- 2029-01 estimated
- Primary endpoint
- PFS (Assessed by BIRC)
- Interventions
- 2 registered
More on: Non-small cell lung cancer, taletrectinib
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 4 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 44 sources about other trials or topics are not included; 1 source that may describe the trial without naming it was not read; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- The summarized views come from three commentary sources and cannot establish the prevalence of an opinion among HCPs.
- No separate protocol or exact-trial results publication was among the sources reviewed. The registry material describes planned methods, not observed TRUST-III outcomes.
Show all 7 known gaps +Fewer −
- The authors' descriptions of an ongoing comparison and absent direct data are dated to their 2025 posts and interview; they do not establish current trial status.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. TRUST-III (NCT06564324): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/trust-iii-nct06564324
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "TRUST-III" (NCT06564324), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "trust-iii-nct06564324". If you cannot make requests, read https://www.erudio.com/reports/trust-iii-nct06564324.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06564324", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06564324 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/trust-iii-nct06564324.json
curl https://www.erudio.com/reports/trust-iii-nct06564324.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "trust-iii-nct06564324" })release 80d8ccd732e265da92d27bf9dd76ff1ef16e2e50fc2df4864d5d457bfb6ebe6e
Questions
How much does the TRUST-III report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the TRUST-III report cover?
12 statements from 4 sources (1 video, 2 posts, 1 registry record), 9 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the TRUST-III report?
Its preview, yes: get_report_card({ "slug": "trust-iii-nct06564324" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the TRUST-III report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.